Vir Biotechnology (NASDAQ:VIR) CAO Sells $70,324.32 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 7,711 shares of Vir Biotechnology stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $9.12, for a total transaction of $70,324.32. Following the completion of the sale, the chief accounting officer directly owned 61,902 shares of the company’s stock, valued at approximately $564,546.24. The trade was a 11.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Brent Sabatini also recently made the following trade(s):

• On Tuesday, February 24th, Brent Sabatini sold 1,430 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.53, for a total transaction of $13,627.90.
• On Monday, February 23rd, Brent Sabatini sold 1,829 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.45, for a total transaction of $13,626.05.
• On Friday, February 13th, Brent Sabatini sold 1,530 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.79, for a total value of $11,918.70.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR opened at $8.57 on Wednesday. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $10.94. The business has a 50-day moving average of $8.16 and a two-hundred day moving average of $6.65. The stock has a market capitalization of $1.20 billion, a P/E ratio of -2.71 and a beta of 1.65.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The business had revenue of $64.07 million for the quarter, compared to analyst estimates of $19.91 million. During the same quarter in the prior year, the firm posted ($0.76) EPS. The firm’s revenue for the quarter was up 417.8% on a year-over-year basis. As a group, research analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its position in shares of Vir Biotechnology by 2,088.4% in the first quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock valued at $1,739,000 after acquiring an additional 256,037 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Vir Biotechnology during the first quarter worth $359,000. Goldman Sachs Group Inc. raised its stake in Vir Biotechnology by 43.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock valued at $4,813,000 after purchasing an additional 225,544 shares during the last quarter. Woodline Partners LP raised its stake in Vir Biotechnology by 245.6% during the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after purchasing an additional 331,701 shares during the last quarter. Finally, Focus Partners Wealth boosted its holdings in Vir Biotechnology by 15.3% in the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after purchasing an additional 2,566 shares during the period. 65.32% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the company. Needham & Company LLC increased their price target on Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. HC Wainwright boosted their price objective on shares of Vir Biotechnology from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Evercore reiterated an “outperform” rating and issued a $18.00 target price on shares of Vir Biotechnology in a research note on Tuesday, February 24th. Finally, Morgan Stanley lifted their target price on shares of Vir Biotechnology from $20.00 to $24.00 and gave the stock an “overweight” rating in a report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $20.44.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.